Novel ceramic bone replacement material Osbone® in a comparative in vitro study with osteoblasts.

Calcium phosphate ceramics are widely used in bone regeneration due to their biocompatibility and structural similarity to natural bone. Among these, hydroxyapatite (HA) is a standard material for bone grafting applications. While established materials like Cerasorb M(®) and Bio-Oss(®) have been extensively studied, newer alternatives such as Osbone(®) are being evaluated for improved performance. Prior research has shown that osteoblast proliferation and differentiation are critical for successful bone integration with graft materials. However, the specific behavior of osteoblasts on Osbone(®) remains less characterized. This gap motivated a direct comparison of Osbone(®) with existing calcium phosphate grafts. The study aimed to clarify how Osbone(®) supports cell adhesion, proliferation, and osteogenic differentiation. No prior work had resolved the comparative performance of Osbone(®) in these aspects. Understanding these interactions is essential for advancing graft material design.

This study aimed to evaluate the in vitro performance of Osbone(®), a novel hydroxyapatite-based bone graft material. The specific problem addressed was the lack of comparative data on Osbone(®) relative to established grafts like Cerasorb M(®) and Bio-Oss(®). The motivation was to determine whether Osbone(®) could support osteoblast proliferation and differentiation similarly to or better than existing options. The study focused on measuring cell adhesion, proliferation, and osteogenic differentiation on Osbone(®). Researchers sought to quantify these effects using DNA content, LDH activity, and ALP activity. The goal was to assess Osbone(®)'s potential for in vivo applications. The study also aimed to compare Osbone(®) with two established materials in the same experimental conditions. This comparison would help identify whether Osbone(®) offers any advantages in bone regeneration.

The study used SaOS-2 osteoblasts cultured on Osbone(®), Cerasorb M(®), and Bio-Oss(®) materials. Cell adhesion was assessed through MTT staining, which detects viable cells. Quantitative measures included DNA content and lactate dehydrogenase (LDH) activity to evaluate proliferation. Scanning electron microscopy (SEM) provided qualitative insights into cell morphology. Alkaline phosphatase (ALP) activity was measured to assess osteogenic differentiation. Gene expression analysis using reverse transcriptase PCR examined osteogenic markers. The experiment spanned 28 days of cultivation to capture long-term effects. All measurements were conducted under standardized in vitro conditions to ensure comparability.

MTT staining confirmed viable cell attachment on all three materials after one day. DNA content and LDH activity showed significant proliferation on Osbone(®) and Cerasorb M(®), but not on Bio-Oss(®) after 28 days. Scanning electron microscopy revealed well-spread cell morphology on Osbone(®) and Cerasorb M(®). ALP activity increased over time on both Osbone(®) and Cerasorb M(®). Gene expression analysis detected osteogenic markers like ALP, osteonectin, osteopontin, and bone sialoprotein II on Osbone(®) and Cerasorb M(®). No such expression was observed on Bio-Oss(®) during the study period. These findings suggest Osbone(®) supports osteoblast proliferation and differentiation. The results indicate Osbone(®) is a viable alternative to existing graft materials.

The study found that Osbone(®) supports osteoblast proliferation and osteogenic differentiation in vitro. These findings align with the observed ALP activity and gene expression patterns. The material's performance is comparable to Cerasorb M(®) but not to Bio-Oss(®). The absence of proliferation on Bio-Oss(®) suggests limitations in its osteoblast support. The well-spread cell morphology on Osbone(®) indicates favorable cell-material interactions. The increase in ALP activity supports the material's role in promoting osteogenesis. Gene expression data further confirms the osteogenic potential of Osbone(®). These results suggest Osbone(®) is a promising candidate for bone graft applications.